Gonorrhea Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

Global Gonorrhea Therapeutics Market 2023-2027

The Global Gonorrhea Therapeutics Market size is estimated to grow by USD 506.68 million at a CAGR of 5.47% between 2022 and 2027.

In the Global Gonorrhea Therapeutics Market, the increasing utilization of advanced diagnostic tests, notably nucleic acid amplification tests (NAATs), marks a significant development. These tests play a crucial role in driving demand for gonorrhea therapeutics by accurately detecting Neisseria gonorrhoeae infection. Moreover, diagnostic screening, facilitated by these tests, emerges as a vital strategy in curbing the spread of the infection to the upper genital tract, particularly considering the often asymptomatic nature of gonorrhea, especially in women. With traditional culture and nucleic acid hybridization also available for confirmation, the advent of NAATs is expected to positively impact the market, enhancing diagnosis accuracy and treatment efficacy. This market research and growth report also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Gonorrhea Therapeutics Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

Distribution Channel Segment Analysis

Hospital pharmacies

The hospital pharmacies segment is estimated to witness significant growth during the forecast period. There is an increasing adoption of integrated healthcare models across hospitals that emphasize coordinated and patient-centered care. Thus the hospital pharmacies segment plays a crucial role in this approach by ensuring that medications are managed effectively throughout a patient stay, from admission to discharge. 

Get a glance at the market contribution of various segments View a PDF Sample

The hospital pharmacies segment was the largest segment and was valued at USD 670.98 million in 2017. There is an increasing focus by this segment on minimizing medication errors, adverse drug reactions, and hospital readmissions. In addition, hospitals play a major role in  STI testing and diagnosis, including testing for gonorrhea. As a result, it fuels the demand for immediate access to appropriate therapeutics. Therefore, this segment has the expertise to manage complex medication regimens and offer guidance on proper administration, dosing, and monitoring, ensuring that patients receive optimal care. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Therapy Segment Analysis

Monotherapy

The main feature of the monotherapy segment is that it uses one single drug at a time to treat the disease. This segment mainly comprises the use of either oral cefixime or IM ceftriaxone for the treatment of gonorrhea. One of the key advantages of this segment which fuels its adoption includes low side effects, owing to the use of a single drug. In addition, factors such as the better tolerability of the drug regimen and the absence of drug-drug interactions are significantly contributing to the growth of this segment. In the past few decades, there has been an increasing adoption of a monotherapy regimen involving a dose of 400 mg cefixime orally or 125-1000 mg ceftriaxone IM or intravenously (IV) for first-line therapy for gonorrhea. Some of the main factors that fuel its use include the high efficacy of these drugs, ease of administration of oral cefixime, cost-effectiveness, and high potency of ceftriaxone IM or IV. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Combination therapy

Combination therapy includes the use of more than one medication for the treatment of a condition.  This segment mainly comprises a combination of various drugs. In addition, this therapy mainly includes the use of either oral cefixime or IM ceftriaxone with azithromycin for the treatment of gonorrhea. The main advantage of combination therapy when compared to monotherapy includes its application in bacterial infections such as gonorrhea, is the bacterial strain's limited ability to develop drug resistance, as the bacterium is less likely to gain resistance to multiple drugs administered simultaneously. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. One of the main countries that is significantly contributing to the growth of the market in North America is the US due to the presence of prominent market players such as Merck and Pfizer. These market players offer a wide range of differentiated antibiotics, which has fuelled their adoption among both patients and physicians alike. In addition, the increasing prevalence of  STDs, including gonorrhea is also significantly contributing to the market growth.

Furthermore, there is rising access to coverage of drugs used to treat STDs, such as HIV/AIDS in the US which is positively impacting the market. For instance, the Affordable Care Act offers better access to healthcare coverage and more health insurance options for STDs to people living in the US which is positively impacting the market. Hence, such factors are expected to drive the market growth in the region during the forecast period.

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Apotex Inc: The company offers gonorrhea therapeutics such as Apotex Ceftriaxone Injection.

• Aurobindo Pharma Ltd.
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Debiopharm International SA
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Lupin Ltd.
• Mayne Pharma Group Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Therapyx Inc.
• Entasis Therapeutics

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is addressing syndromic sexually transmitted infections, including asymptomatic cases, through testing and treatment algorithms, amid the prevalence of sexually transmitted diseases (STDs). National campaigns aim to mitigate the burden of gonorrhea and HIV infection, aligning with guidelines to combat social stigma and improve diagnostic capability in STD clinics. The dual therapy segment, featuring ceftriaxone and azithromycin, stands as the first-line regimen supported by clinical studies, emphasizing the efficacy of high-dose ceftriaxone monotherapy against Neisseria gonorrhoeae, including extragenital infections. Technological advancements and innovative solutions address consumer needs while raising awareness and addressing environmental concerns. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

One of the key factors driving the market growth is the rising prevalence of gonorrhea. The market's growth is propelled by the increasing prevalence of gonorrhea, a syndromic sexually transmitted infection (STI) causing growing concern worldwide. Despite some cases being asymptomatic, the burden of gonorrhea remains significant, with approximately 700,000 new cases identified annually in the US alone, as reported by the CDC. The rising incidence rate, exemplified by the 2009 CDC report indicating 301,174 cases of gonorrhea with an incidence rate of 99.1 cases per 100,000 US population, underscores the urgent need for effective testing and treatment algorithms.

Several factors contribute to the escalating prevalence of gonorrhea, including growing awareness, improved healthcare access, and the availability of diagnostic tests. However, challenges such as resistance patterns, reporting practices, and financial constraints faced by public health officials impede precise disease pattern monitoring. These factors drive the demand for gonorrhea treatment, particularly within the dual therapy segment, which utilizes a combination of ceftriaxone and azithromycin as the first-line regimen.

Guidelines and national campaigns aimed at addressing sexually transmitted diseases (STDs) play a crucial role in combating the spread of gonorrhea and reducing the associated social stigma. STD clinics and clinical studies contribute to advancing diagnostic capability and treatment efficacy, with a focus on extragenital Neisseria gonorrhoeae (NG) infections. Technological advancements and innovative solutions further enhance the effectiveness of gonorrhea management, aligning with consumer needs and environmental concerns. Overall, heightened awareness, coupled with advancements in testing, treatment, and prevention strategies, is expected to drive market growth during the forecast period, as stakeholders continue to prioritize efforts to combat the spread of gonorrhea and address its multifaceted challenges.

Significant Market Trends

A key factor shaping the market growth is the advent of vaccines for the prevention of gonorrhea. There is a growing concern across the world regarding the prevalence of gonorrhea as it is significantly impacting the reproductive health of people and increasing the spread of the human immunodeficiency virus (HIV). due to the rapid emergence of antibiotic-resistant strains of this bacterium., the conventional treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae.

As a result, the prevention of the disease seems to be the ideal approach for containing the spread of Neisseria gonorrhoeae. Therefore, there is an increasing development of novel vaccines that can prevent gonorrhea. For example, the antigens contained in the MeNZB vaccine, which was originally developed to stop the meningitis outbreak in New Zealand during 2004-2006, have shown some clinical efficacy against the gonococcal bacteria. Hence, such factors are positively impacting the market which in turn will drive the market growth during the forecast period.

Major Market Challenges

Regulatory hurdles related to gonorrhea therapeutics are a major challenge hindering market growth. The Regulatory approvals for new therapeutics for gonorrhea is a complex and expensive process. As a result, such regulatory requirements for clinical trials and drug approvals can pose a significant threat to market growth. The process of executing clinical trials to estimate the safety and efficacy of new gonorrhea therapeutics is a resource-intensive process.

Moreover, there is extensive documentation associated with the submission of applications for regulatory approval including the preclinical and clinical trial data, safety profiles, manufacturing details, and more. Additionally, some of the prominent authorities that conduct the review process of submitted data include regulatory agencies, such as the US Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe which is a time-consuming process. Hence, such factors are negatively impacting the market which in turn will hinder the market growth during the forecast period.

Buy Now Full Report and Discover More

Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Gonorrhea Therapeutics Market Customer Landscape

Market Analyst Overview

The global market is witnessing a surge in demand for services addressing Sexually transmitted infection services and Syndromic sexually transmitted infections. Addressing Asymptomatic cases is crucial, driving the need for advanced Testing and treatment algorithms highlighted in journals like Journal AANP and Journal of Infectious Diseases. With rising concerns about Sexually transmitted diseases (STDs), governments and private sectors are enhancing Diagnostic capability and ensuring robust Supply chain for Diagnosis and treatment. National campaigns and guidelines by organizations like WHO focus on mitigating the Burden of gonorrhea and HIV infection, combating Social stigma, and strengthening STD clinics. The market witnesses innovation in Dual therapy segment and High-dose ceftriaxone monotherapy, supported by clinical studies and initiatives by entities like European Union against Sexually Transmitted Infections.

Technological advancements drive Innovative Gonorrhea Therapeutics solutions addressing Consumer needs while ensuring Environmental concerns and Sustainability across sectors like Construction, Automotive, and Electronics, contributing to Market expansion fueled by Government initiatives. The Gonorrhea Therapeutics Industry faces challenges such as Initial investment requirements and Infrastructure limitations, compounded by Policy uncertainty and Supply chain disruptions. Additionally, Intermittency in treatment outcomes and Competition from alternative technologies impact market dynamics. Public perception and Lack of awareness about gonorrhea therapeutics pose further hurdles. However, amidst these challenges lie Opportunities for growth driven by Technological innovations. Overcoming these obstacles requires strategic planning, investment in R&D, and effective communication to enhance awareness and combat public stigma. Despite the complexities, the industry remains resilient, with the potential for significant advancements in gonorrhea treatment methodologies.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Distribution Channel Outlook 
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Therapy Outlook 
  • Monotherapy
  • Combination therapy
• Geography Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Brazil

Gonorrhea Therapeutics Market Scope
Report Coverage	Details
Page number	162
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.47%
Market growth 2023-2027	USD 506.68 million
Market structure	Fragmented
YoY growth 2022-2023(%)	4.98
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 39%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Ltd., Debiopharm International SA, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Therapyx Inc., and Entasis Therapeutics
Market dynamics	Market trends and analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2023 and 2027
• Precise estimation of the market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Market growth analysis across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Market forecasting of factors that will challenge the growth of the key market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch